Meri Ramela

Biochemistry, Genetics and Molecular Biology · Life Sciences

6h-index146citations18works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(9), Prostate Cancer Treatment and Research(8), Hormonal Regulation and Hypertension(6), Cancer, Hypoxia, and Metabolism(3), Veterinary Pharmacology and Anesthesia(3)

Publications18 total

Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
2023Open Access
Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
2023Open Access
Supplementary Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
2023Open Access
Supplementary Data from First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
2023Open Access
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
Molecular Cancer Therapeutics·2022· 21 citedOpen Access
Rapid Absorption of Naloxone from Eye Drops
Pharmaceuticals·2022Open Access
Abstract 1250: ODM-208, a novel, small-molecule CYP11A1 inhibitor, demonstrates strong inhibition of steroid biosynthesis and antitumor activity in castration-resistant prostate cancer (CRPC) model
Cancer Research·2021
22P Safety profile and therapeutic efficacy of CYP11A1 inhibitor ODM-208 in cellular models and intact male dogs
Annals of Oncology·2020
CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer
Endocrine Abstracts·2019
SUN-LB002 CYP11A1 Inhibition as a Therapeutic Approach for the Treatment of Castration Resistant Prostate Cancer
Journal of the Endocrine Society·2019· 4 citedOpen Access
CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer
Annals of Oncology·2018· 1 citedOpen Access
CYP11A1 inhibition as a therapeutic approach for the treatment of castration resistant prostate cancer.
Journal of Clinical Oncology·2018· 4 cited
Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1
The Journal of Steroid Biochemistry and Molecular Biology·2018· 22 citedOpen Access
ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
Annals of Oncology·2017· 3 cited
Pharmacokinetics of Intravenous Levosimendan and Its Metabolites in Subjects With Hepatic Impairment
The Journal of Clinical Pharmacology·2008· 39 cited
Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men
European Journal of Pharmaceutical Sciences·2007· 21 cited
Comparison of cardiopulmonary effects of dexmedetomidine administered as a constant rate infusion without loading dose in sheep and goats anaesthetised with sevoflurane
Small Ruminant Research·2006· 20 cited
Comparative pharmacokinetics of medetomidine enantiomers in goats and sheep during sevoflurane anaesthesia
Journal of Veterinary Pharmacology and Therapeutics·2006· 11 cited

Frequent Co-authors

Riikka Oksala(13), Petteri Rummakko(13), Reetta Riikonen(12), Gerd Wohlfahrt(12), Mari Karimaa(12), Outi Simola(8), Päivi Taavitsainen(7), Annamari Vuorela(7), Mika Mustonen(6), Henna Kettunen(6), Marcin Chruściel(6), Heikki Joensuu(6), Karim Fizazi(6), Stefan Karlsson(5), Pasi Hakulinen(5), Tapio Utriainen(5), Pirjo Vehmaan-Kreula(4), Pekka Kallio(3), Kati Räsänen(3), Jaakko Puttonen(2)